It's a fair point that Teva wouldn't want MSB to starve. However, I think it's perhaps unlikely that they would pony up some $$ outside a contracted milestone payment, which as I say, would typically come with a significant achievement. Maybe MSB could issue new equity to Teva if they needed $$ outside of the existing agreement.
Pure speculation on my part of course.
Incidentally, a new report out from Roberts today on GVHD, which values MSB at $9.73 base. In his opinion, the downward trajectory of MSBs price since the all-time high is due to "primarily a reflection of market scepticism in the United States regarding the commercial prospects of regenerative medicine ahead of any meaningful Phase III data, combined with the fact that Mesoblast is the 'tall poppy' in the space with a market capitalisation north of a billion US dollars".
Amongst other risks, he cites "High burn rate" at no. 3
MSB Price at posting:
$4.02 Sentiment: None Disclosure: Not Held
(20min delay)